NASDAQ$VREX
Varex Imaging Corp · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Varex Imaging reported a decrease in net loss and an increase in revenue for the first quarter of fiscal year 2025.
Varex Imaging Corporation reported a net loss of $0.1 million for the three months ended January 3, 2025, an improvement from a $0.4 million net loss in the prior quarter. Revenues increased to $199.8 million, up from $190.0 million in the previous quarter, driven by strong performance in both Medical and Industrial segments.
- Net loss improved to $0.1 million from $0.4 million in the prior quarter.
- Total revenues increased by $9.8 million, or 5.2%, quarter-over-quarter.
- Medical segment revenue grew by 3.4% and Industrial segment revenue grew by 10.2%.
- Gross profit increased by $11.4 million, or 20.0%, quarter-over-quarter.
Headline financials
Revenue & EPS history
Varex Imaging · Revenue · Quarterly
$200M
Revenue by segment
Varex Imaging · $232M total across 2 segments · Q3 2023
- Medical$175M+5.0%75.5%
- Industrial$56.8M+19.8%24.5%
Forward guidance
The company anticipates continued challenges and opportunities in the coming periods, with a focus on innovation and strategic investments.
Tailwinds
- Optimism for increased opportunities in China due to a new stimulus program including the healthcare industry.
- Continued investment in research and development to bring new products to market for global OEM customers.
- Industrial business benefits from research and development investment and manufacturing economies of scale from the Medical side.
- Industrial business benefits from long-term service agreements for Linatron® products.
- Active pursuit of new potential applications for non-destructive testing products.
Headwinds
- Uncertain economic and geopolitical environment, supply chain and logistic challenges, and geopolitical tensions.
- Potential for renewed inflation, higher interest rates and capital costs, increased shipping costs, and supply shortages.
- Negative impact on Medical business from the Chinese government's anti-corruption campaign related to the healthcare industry.
- Potential for additional tariffs or retaliatory actions to impact business.
- Uncertainty regarding the final Pillar Two model rules and their potential impact on the effective tax rate.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-4.3%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-3.0%
Avg return
30 days after
37%
15 / 41 earnings
Positive
+22.1%
Q1 2021
Best reaction
-34.7%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -16.9% | -14.9% | — | |
| Q1 2026 | -3.8% | -4.5% | -23.6% | |
| Q4 2025 | -13.7% | -7.1% | +3.6% | |
| Q2 2025 | -20.5% | -13.9% | -2.7% | |
| Q1 2025 | -19.3% | -11.6% | -15.7% | |
| Q4 2024 | +9.2% | +17.8% | +1.8% | |
| Q3 2024 | -12.2% | -21.2% | -15.6% | |
| Q2 2024 | -6.0% | -4.4% | -6.8% | |
| Q1 2024 | -8.4% | -8.4% | -8.6% | |
| Q4 2023 | +3.1% | +1.7% | +12.7% | |
| Q3 2023 | -3.8% | -2.6% | -15.5% | |
| Q2 2023 | +17.6% | +25.5% | +25.6% | |
| Q1 2023 | -10.0% | -7.2% | -14.6% | |
| Q4 2022 | +3.8% | -1.6% | -10.7% | |
| Q3 2022 | +4.1% | -0.6% | -0.3% | |
| Q2 2022 | +11.5% | +11.5% | +15.8% | |
| Q1 2022 | -5.3% | -8.6% | -4.8% | |
| Q4 2021 | +17.1% | +15.0% | +8.7% | |
| Q3 2021 | +1.9% | +7.3% | +10.2% | |
| Q2 2021 | +2.6% | +2.0% | +6.1% | |
| Q1 2021 | +22.1% | +19.3% | +21.0% | |
| Q4 2020 | -3.2% | +1.0% | +16.6% | |
| Q3 2020 | -21.2% | -21.1% | -34.3% | |
| Q2 2020 | -34.7% | -32.9% | -38.3% | |
| Q1 2020 | -5.3% | -5.3% | -25.3% | |
| Q4 2019 | -9.7% | -7.5% | -3.5% | |
| Q3 2019 | -15.8% | -13.3% | -5.0% | |
| Q2 2019 | -9.1% | -8.1% | -16.4% | |
| Q1 2019 | +15.7% | +8.8% | +15.0% | |
| Q4 2018 | -8.3% | -1.8% | -10.8% | |
| Q3 2018 | -25.7% | -25.5% | -17.8% | |
| Q2 2018 | -1.6% | -0.3% | +1.1% | |
| Q1 2018 | -18.5% | -15.9% | -15.8% | |
| Q4 2015 | -1.2% | -0.2% | +7.2% | |
| Q4 2017 | +1.8% | +2.6% | +10.3% | |
| Q3 2016 | +0.8% | -0.2% | +9.4% | |
| Q3 2017 | -8.2% | -5.1% | +1.3% | |
| Q2 2016 | +0.2% | +0.2% | -3.3% | |
| Q2 2017 | +0.7% | +1.2% | +3.0% | |
| Q1 2017 | -2.4% | -5.1% | -0.3% | |
| Q4 2016 | -2.4% | -5.1% | -0.3% | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro